HP007 / Parr Biotechnology - LARVOL DELTA

HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=44 | Not yet recruiting | Sponsor: Parr Biotechnology (Hebei) Co., Ltd.

Monotherapy • New P1 trial • Breast Cancer • Head and Neck Cancer • Hepatocellular Cancer • Melanoma • Oncology • Prostate Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

A broad-spectrum SARS-CoV-2 RBD vaccine with selected high-impact mutations and novel adjuvant induces durable T cell response and broad protection in mice. (PubMed, Front Cell Infect Microbiol) - "Rationally designed with key high-impact mutation sites, M5-RBD effectively overcomes SARS-CoV-2 variant immune evasion and elicits broad-spectrum neutralizing antibodies. The combination with HP007 adjuvant enhances immune protection, providing a promising strategy for the development of next-generation COVID-19 vaccines."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases